• Manon Kissel, Isabelle Martel-Lafay, Justine Lequesne, Jean-Christophe Faivre, Cécile Le Péchoux, Dinu Stefan, Victor Barraux, Cédric Loiseau, Jean-Michel Grellard, Serge Danhier, Delphine Lerouge, Christos Chouaid, Radj Gervais, and Juliette Thariat.
• Centre de lutte contre le cancer François Baclesse/ ARCHADE, radiotherapy department, 3 avenue du Général Harris, 14000, Caen, France. manon.kissel@gustaveroussy.fr.
• Bmc Cancer. 2019 Dec 19; 19 (1): 1237.

BackgroundStereotactic irradiation (SBRT) is a standard of care for inoperable stage I lung cancer and brain oligometastases from lung cancer but is controversial for extracranial oligometastases. We assessed outcomes of lung cancer patients with extracranial metastases in oligometastatic, oligorecurrent, oligopersistent and oligoprogressive settings ("oligometastatic spectrum") under strategies using SBRT +/- systemic treatments.MethodsA retrospective multicentric study of consecutive lung cancer adult patients with 1-5 extracranial metastases treated with SBRT was conducted.ResultsOf 91 patients (99 metastases, median age 63, 64.8% adenocarcinomas, 19.8% molecular alterations), 11% had oligometastases, 49.5% oligorecurrence, 19.8% oligopersistence and 19.8% oligoprogression. Of 36% of patients under systemic treatments at initiation of SBRT, systemic treatment interruption was performed in 58% of them. With median follow up of 15.3 months, crude local control at irradiated metastases was 91%, while median distant progression-free survival (dPFS) and overall survival were 6.3 and 28.4 months (2-year survival 54%). Initial nodal stage and oligometastatic spectrum were prognostic factors for dPFS; age, initial primary stage and oligometastatic spectrum were prognostic factors for survival on multivariate analysis. Patients with oncogene-addicted tumors more frequently had oligoprogressive disease. Repeat ablative irradiations were preformed in 80% of patients who had oligorelapses. Worst acute toxicities consisted of 5.5% and one late toxic death occurred.ConclusionThe oligometastatic spectrum is a strong prognosticator in patients undergoing SBRT for extracranial metastases. Median survival was over two years but dPFS was about 6 months. Continuation of systemic therapy in oligoprogressive patients should be investigated.

32 keywords...

hide…